Willems L, Thienpont E, Kerkhofs P, Burny A, Mammerickx M, Kettmann R
Faculté des Sciences Agronomiques, Gembloux, Belgium.
J Virol. 1993 Feb;67(2):1086-9. doi: 10.1128/JVI.67.2.1086-1089.1993.
Intradermal injection of a cloned bovine leukemia virus (BLV) provirus (pV344) into sheep allowed direct evaluation of intrastrain variability. A sheep was injected with pV344 DNA mixed with DEAE-dextran and became persistently infected with BLV strain 344. After 18 months, DNA was extracted from peripheral blood leukocytes from a single 0.5-ml blood sample. The long terminal repeat (LTR) and the env gene were amplified by using the polymerase chain reaction, cloned, and sequenced. Nineteen independent LTR clones (0.6-kb inserts) and 16 env clones (1-kb inserts) were analyzed. The in vivo rate of nucleotide change was 0.009%/year (two mutations out of 14,464 bp in 1.5 years), corresponding to only one amino acid change in the env gene. Five point mutations (all transitions), corresponding to a modification rate of 0.034%/year (five mutations out of 9,709 bp in 1.5 years), were identified in the LTR. As a control for Taq DNA polymerase errors, the same procedure using pV344 plasmid DNA was carried out. Out of 9,944 bp sequenced, three point mutations were found (i.e., one misincorporation in 3,315 nucleotides). These data demonstrate the extremely low level (or absence) of intrastrain variability of BLV in vivo. Consequently, BLV persistence in the infected host does not seem to result from an escape mutant strategy, in sharp contrast with the high mutation rates observed in the lentivirus family. The lack of genetic variation supports the possibility of successful vaccine against BLV and probably against the related human T-cell leukemia viruses.
将克隆的牛白血病病毒(BLV)前病毒(pV344)皮内注射到绵羊体内,可直接评估株内变异性。给一只绵羊注射了与二乙氨基乙基葡聚糖混合的pV344 DNA,该绵羊被BLV 344株持续感染。18个月后,从0.5毫升血液样本中的单个外周血白细胞中提取DNA。使用聚合酶链反应扩增长末端重复序列(LTR)和env基因,进行克隆并测序。分析了19个独立的LTR克隆(0.6 kb插入片段)和16个env克隆(1 kb插入片段)。体内核苷酸变化率为0.009%/年(1.5年内14464个碱基对中有两个突变),相当于env基因中仅一个氨基酸变化。在LTR中鉴定出五个点突变(均为转换),对应修饰率为0.034%/年(1.5年内9709个碱基对中有五个突变)。作为Taq DNA聚合酶错误的对照,使用pV344质粒DNA进行相同的操作。在测序的9944个碱基对中,发现三个点突变(即3315个核苷酸中有一个错配)。这些数据表明,体内BLV株内变异性极低(或不存在)。因此,与慢病毒家族中观察到的高突变率形成鲜明对比的是,BLV在受感染宿主中的持续存在似乎不是由逃逸突变策略导致的。缺乏遗传变异支持了成功研制抗BLV疫苗以及可能抗相关人类T细胞白血病病毒疫苗的可能性。